STX — Shield Therapeutics Share News
0.000.00%
Last trade - 00:00- £114.14m
- £126.00m
- $32.18m
REG - Shield Therapeutics - Approval for ACCRUFeR in China expected in Q1 2026
AnnouncementREG - Shield Therapeutics - Q4 2025 Trading Update
AnnouncementREG - Shield Therapeutics - Block listing 6 Monthly Return
AnnouncementREG - Shield Therapeutics - Total Voting Rights
AnnouncementREG - AIM - AIM Notice - 23/12/2025
AnnouncementREG - Shield Therapeutics - FDA approves extension for ACCRUFeR®
AnnouncementREG - Shield Therapeutics - Block Listing Application
AnnouncementRCS - Shield Therapeutics - Shield Wins Gold at Titan Branding Awards
AnnouncementREG - Shield Therapeutics - Amends Senior Secured Debt Financing
AnnouncementREG - Shield Therapeutics - Initiation of a Phase II Clinical Trial in Japan
AnnouncementREG - Shield Therapeutics - ACCRUFeR Pediatric PK Results to be Presented
AnnouncementREG - Shield Therapeutics - ACCRUFeR receives Authorisation by Korean Ministry
AnnouncementREG - Shield Therapeutics - Q3 2025 Trading Update
AnnouncementREG - Shield Therapeutics - Grant of Share Options to Chief Executive Officer
AnnouncementREG - Shield Therapeutics - Total Voting Rights
AnnouncementREG - Shield Therapeutics - Positive efficacy and tolerance in pediatric trial
AnnouncementREG - AIM - AIM Notice - 19/09/2025
AnnouncementREG - Shield Therapeutics - £1.5 million placing supporting growth of ACCRUFeR
AnnouncementREG - Shield Therapeutics - ACCRUFeR® assigned Priority Review in US by FDA
Announcement